Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for HFrEF with moderate to severe obstructive sleep apnea
ChiCTR2100049834Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF) and obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Respiratory Disorder Index. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2100049834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049834.